Age-related injury responses of human oligodendrocytes to metabolic insults: link to BCL-2 and autophagy pathways

Milton Guilherme Forestieri Fernandes, Julia Xiao Xuan Luo, Qiao-Ling Cui, Kelly Perlman, Florian Pernin, Moein Yaqui, Jeffery A. Hall, Roy Dudley, Myriam Sour, Charles P. Couturier, Kevin Petrecco, Catherine Larochelle, Luke M. Healy, Jo Anne Stratton, Timothy E. Kennedy & Jack P. Antel

Myelin destruction and oligodendrocyte (OL) death consequent to metabolic stress is a feature of CNS disorders across the age spectrum. Using cells derived from surgically resected tissue, we demonstrate that young (<age 5) pediatric-aged sample OLs are more resistant to in-vitro metabolic injury than fetal O4+ progenitor cells, but more susceptible to cell death and apoptosis than adult-derived OLs. Pediatric but not adult OLs show measurable levels of TUNEL+ cells, a feature of the fetal cell response. The ratio of anti- vs pro-apoptotic BCL-2 family genes are increased in adult vs pediatric (<age 5) mature OLs and in more mature OL lineage cells. Lysosomal gene expression was increased in adult and pediatric compared to fetal OL lineage cells. Cell death of OLs was increased by inhibiting pro-apoptotic BCL-2 gene and autophagy activity. These distinct age-related injury responses should be considered in designing therapies aimed at reducing myelin injury.
Oligodendrocyte (OL) injury with subsequent cell death consequent to metabolic insults is a feature of a number of acquired disorders of the central nervous system (CNS) across the age spectrum. These include adult-onset multiple sclerosis (MS) and focal and diffuse injury in children. In the acute lesions in MS, there is limited loss of OLS, with inconsistent evidence of active cell death response mechanisms as measured by presence of OLS with morphologic features of apoptosis or cleaved caspase-3. Surviving OLS show disruption of terminal cell processes consistent with a dying-back phenomenon, which may reflect sub-lethal injury that is potentially reversible and allow them to contribute to subsequent myelin repair. In chronic lesions, there is universal loss of OLS. Although immune-mediated mechanisms are considered to underlie initial lesion formation, analysis of MS tissues provides evidence of local ischemia/hypoxia contributing to ongoing injury. These responses are attributed to disturbance of the micro-circulation due to focal edema or local production of toxic metabolites that interfere with energy metabolism. Dutta and Trapp, using tissue micro-dissected from established MS lesions, found no evidence of activation of pro-apoptotic cell death pathways to account for the OL loss. The variable myelin repair in MS is mainly attributed to OPCs present in lesions. Our previous studies suggest that OPCs in MS lesions are even more susceptible to injury than mature OLS.

Across the pediatric age range, metabolic insults can result in permanent motor and cognitive deficits. Underlying causes for such insults include systemic metabolic disorders and infection, trauma, and prolonged seizures. Such insults in full term newborn infants are referred to as neonatal hypoxic/ischemic encephalopathy (reviewed in 21). The pathologic features include involvement of subcortical and central white matter similar to what is observed in periventricular leukomalacia that occurs in pre-term infants. Pre-myelinating oligodendrocytes; phenotype typically characterized as O4+/platelet derived growth factor receptor α (PDGF-R+) /NG2+ progenitor cells, remain abundant after birth and are particularly vulnerable to this form of injury. Most injury was considered to be via necrosis although some degree of apoptosis could be observed. We identified such a cell population in our previous single cell RNA sequencing analysis of surgically derived pediatric age brain samples. Cell death of OPCs was shown to occur by apoptosis in an in vivo neonatal rat model of hypoxic-ischemic injury. Pre-myelinating oligodendrocytes; phenotype typically characterized as O4+/platelet derived growth factor receptor α (PDGF-R+) /NG2+ progenitor cells, remain abundant after birth and are particularly vulnerable to this form of injury.

In our current study we demonstrate the age-related differences in susceptibility of human OL lineage cells to metabolic injury and relate these to the underlying molecular mechanisms, specifically the interaction of BCL-2 family molecules that regulate the intrinsic apoptotic pathway (illustrated in Supplementary Fig. 1) and the autophagy pathway. The BCL-2 family is divided in three groups: the pro-apoptotic effector molecules BAX and BAK, the anti-apoptotic BCL-2, BCL-XL (encoded by BCL2L1 gene), BCL-2A1, MCL-1, BCL-W (encoded by BCL2L2 gene) and BCL-B (encoded by BCL2L10 gene) and the sensor/activator molecules from the BH3-only subfamily (BAD, BIM, BID and others). Under stress, BH3-only subfamily members are activated or upregulated. They can bind to the anti-apoptotic family members, preventing their interaction with BAX and BAK, or bind directly to BAX and BAK to result in their release from inhibition, triggering the apoptotic pathway. The BCL-2: BAX ratio has been used as a measure of the relative expression of anti- vs pro-apoptotic molecules. In vitro studies indicate that pro-apoptotic family members are constitutively expressed at a considerably higher level than anti-apoptotic family members in rat OPCs. With differentiation, the expression of anti- vs pro-apoptotic members increases, potentially increasing resistance to apoptosis. We provide evidence for the significance of the BCL-2 pathway in protecting human OLS.

Autophagy reflects a metabolic switch from anabolism to catabolism with degraded cellular components being used as a source of energy. This process initially supports the survival of the cell under nutrient starvation. However, the formation of autophagosomes without a further fusion with lysosomes can be detrimental to the cell, ultimately leading to cell death (autophagic cell death); such cell death can occur either independently or independently of apoptosis. In a neonatal mouse model of asphyxia, OL death was increased by preventing autophagy. Neuman et al. found that fasting or treatment with metformin could reverse age-related decreases in metabolic function and protect against DNA damage in aged rat A2B5+ OPCs, resulting in enhanced myelination capacity. In a previous study we had observed that metabolic stress conditions induced an enhanced autophagy response in adult human OLS as measured by increased expression of LC3. We now address the role of autophagy in regulating OL cell death in response to metabolic insult.

For our study, we isolated OLS from surgical resections of pediatric and adult cases to (i) determine their relative susceptibility to metabolic insult (LG/NG) conditions; and (ii) identify molecular signatures related to cell death; such cell death can occur either dependently or independently of apoptosis. In a neonatal mouse model of asphyxia, OL death was increased by preventing autophagy. Neuman et al. found that fasting or treatment with metformin could reverse age-related decreases in metabolic function and protect against DNA damage in aged rat A2B5+ OPCs, resulting in enhanced myelination capacity. In a previous study we had observed that metabolic stress conditions induced an enhanced autophagy response in adult human OLS as measured by increased expression of LC3. We now address the role of autophagy in regulating OL cell death in response to metabolic insult.

For our study, we isolated OLS from surgical resections of pediatric and adult cases to (i) determine their relative susceptibility to metabolic insult (LG/NG) conditions; and (ii) identify molecular signatures related to cell death; such cell death can occur either dependently or independently of apoptosis. In a neonatal mouse model of asphyxia, OL death was increased by preventing autophagy. Neuman et al. found that fasting or treatment with metformin could reverse age-related decreases in metabolic function and protect against DNA damage in aged rat A2B5+ OPCs, resulting in enhanced myelination capacity. In a previous study we had observed that metabolic stress conditions induced an enhanced autophagy response in adult human OLS as measured by increased expression of LC3. We now address the role of autophagy in regulating OL cell death in response to metabolic insult.

For our study, we isolated OLS from surgical resections of pediatric and adult cases to (i) determine their relative susceptibility to metabolic insult (LG/NG) conditions; and (ii) identify molecular signatures related to cell death; such cell death can occur either dependently or independently of apoptosis. In a neonatal mouse model of asphyxia, OL death was increased by preventing autophagy. Neuman et al. found that fasting or treatment with metformin could reverse age-related decreases in metabolic function and protect against DNA damage in aged rat A2B5+ OPCs, resulting in enhanced myelination capacity. In a previous study we had observed that metabolic stress conditions induced an enhanced autophagy response in adult human OLS as measured by increased expression of LC3. We now address the role of autophagy in regulating OL cell death in response to metabolic insult.

For our study, we isolated OLS from surgical resections of pediatric and adult cases to (i) determine their relative susceptibility to metabolic insult (LG/NG) conditions; and (ii) identify molecular signatures related to cell death; such cell death can occur either dependently or independently of apoptosis. In a neonatal mouse model of asphyxia, OL death was increased by preventing autophagy. Neuman et al. found that fasting or treatment with metformin could reverse age-related decreases in metabolic function and protect against DNA damage in aged rat A2B5+ OPCs, resulting in enhanced myelination capacity. In a previous study we had observed that metabolic stress conditions induced an enhanced autophagy response in adult human OLS as measured by increased expression of LC3. We now address the role of autophagy in regulating OL cell death in response to metabolic insult.

For our study, we isolated OLS from surgical resections of pediatric and adult cases to (i) determine their relative susceptibility to metabolic insult (LG/NG) conditions; and (ii) identify molecular signatures related to cell death; such cell death can occur either dependently or independently of apoptosis. In a neonatal mouse model of asphyxia, OL death was increased by preventing autophagy. Neuman et al. found that fasting or treatment with metformin could reverse age-related decreases in metabolic function and protect against DNA damage in aged rat A2B5+ OPCs, resulting in enhanced myelination capacity. In a previous study we had observed that metabolic stress conditions induced an enhanced autophagy response in adult human OLS as measured by increased expression of LC3. We now address the role of autophagy in regulating OL cell death in response to metabolic insult.

For our study, we isolated OLS from surgical resections of pediatric and adult cases to (i) determine their relative susceptibility to metabolic insult (LG/NG) conditions; and (ii) identify molecular signatures related to cell death; such cell death can occur either dependently or independently of apoptosis. In a neonatal mouse model of asphyxia, OL death was increased by preventing autophagy. Neuman et al. found that fasting or treatment with metformin could reverse age-related decreases in metabolic function and protect against DNA damage in aged rat A2B5+ OPCs, resulting in enhanced myelination capacity. In a previous study we had observed that metabolic stress conditions induced an enhanced autophagy response in adult human OLS as measured by increased expression of LC3. We now address the role of autophagy in regulating OL cell death in response to metabolic insult.

For our study, we isolated OLS from surgical resections of pediatric and adult cases to (i) determine their relative susceptibility to metabolic insult (LG/NG) conditions; and (ii) identify molecular signatures related to cell death; such cell death can occur either dependently or independently of apoptosis. In a neonatal mouse model of asphyxia, OL death was increased by preventing autophagy. Neuman et al. found that fasting or treatment with metformin could reverse age-related decreases in metabolic function and protect against DNA damage in aged rat A2B5+ OPCs, resulting in enhanced myelination capacity. In a previous study we had observed that metabolic stress conditions induced an enhanced autophagy response in adult human OLS as measured by increased expression of LC3. We now address the role of autophagy in regulating OL cell death in response to metabolic insult.

For our study, we isolated OLS from surgical resections of pediatric and adult cases to (i) determine their relative susceptibility to metabolic insult (LG/NG) conditions; and (ii) identify molecular signatures related to cell death; such cell death can occur either dependently or independently of apoptosis. In a neonatal mouse model of asphyxia, OL death was increased by preventing autophagy. Neuman et al. found that fasting or treatment with metformin could reverse age-related decreases in metabolic function and protect against DNA damage in aged rat A2B5+ OPCs, resulting in enhanced myelination capacity. In a previous study we had observed that metabolic stress conditions induced an enhanced autophagy response in adult human OLS as measured by increased expression of LC3. We now address the role of autophagy in regulating OL cell death in response to metabolic insult.
The pediatric OLs were however more resistant to cell death (% PI+ cells) compared to O4+ cells isolated from fetal human brain samples under LG conditions at 2 days (Fig. 1c) (16.9 ± 4.0% vs 32.1 ± 6.0%; p = 0.06). For the pediatric samples, the proportion of TUNEL+ cells was also statistically higher in LG and NG conditions compared to N1 conditions (Fig. 1c); however, the percentage of TUNEL+ cells under NG conditions was significantly lower than the percentage of PI positive cells (8.2 ± 2.2% vs 30.3 ± 5.7%; p < 0.05) (Fig. 1b, e). For the fetal cells, % TUNEL+ cells was comparable to % PI+ cells (37.5 ± 9.3% vs 43.8 ± 8.9%). As shown in Fig. 1g, h, prolonged (6 day) culture of the adult OLs under LG and NG conditions resulted in a higher % of PI+ cells that was not associated with any significant increase in % TUNEL+ cells. Cell numbers were also reduced under NG vs N1 conditions at day 6 in the adult cell cultures (Fig. 1j, k).
Identification of OL lineage subsets by whole-cell scRNA seq of immediately ex vivo cells. In order to identify sub-populations of OL lineage cells that may have distinct cell death responses, we applied unbiased cluster analysis to the pooled OL-lineage cells across a range of ages (Fig. 2a, b). Figure 2c presents violin plots showing relative expression levels across clusters of selected marker genes. In addition to the three subpopulations mature OLs (mOLs), late OPCs (lOPCs), and early OPCs (eOPCs) as identified in our previous report, we identified an additional PDGFRα− PTPRZ1+ MBP+ population, here labeled as committed pre-OLs (pOLs). A population expressing both immune and oligodendrocyte markers, akin to that described by Jäkel et al., was also identified but not included in this analysis (Supplementary Fig. 3a).

As seen in Fig. 2a, b, mature OLs comprised the large majority of OL lineage cells in both adult and pediatric samples although progenitors were apparently more abundant in the pediatric samples (quantified in Supplementary Fig. 3b). eOPCs were derived entirely from fetal samples.

Contributions of pro- and anti-apoptotic BCL-2 family members to OL susceptibility to metabolic injury. To identify molecular signatures that would help understand the basis for the observed age-related differences in resistance to metabolic insult, we first considered the baseline expression of genes encoding pro- and anti-apoptotic BCL-2 family members in the OLs in our adult and pediatric samples.

Our initial analysis across age groups includes pooled total OL-lineage cells from all our donor samples as for some subsets there were insufficient numbers of cells to compare between individual samples. We divided the BCL-2 family genes into pro-apoptotic (BAX, BAK1) and anti-apoptotic (BCL2A1, BCL2, BCL2L2) categories, and further separated genes whose product activity depends on alternatively spliced products (BCL2L1, MCL1) (Fig. 3a–c). BCL2L10 is not included as it was not captured due to dropout events in sequencing. Actual normalized expression values are presented in Supplementary Dataset 1. As presented in Fig. 3a, for the total OL cluster, the fetal derived OL cells expressed higher levels of pro-apoptotic gene BAX as compared to pediatric and adult donor cells. Comparison of OL sub-populations defined by differentiation stage indicates skewing to greater anti- vs pro-apoptotic gene expression with cell differentiation (Fig. 3b), particularly on comparison of mOLs and pOLs with lOPCs and eOPCs. As shown in Supplementary Fig. 4a, comparisons of different lineages within the pediatric age group indicate that there is skewing to greater anti- vs pro-apoptotic gene expression with cell differentiation. We are unable to draw a statistical conclusion from the adult cohort as the numbers of progenitor cells are too limited (Supplementary Fig. 4b).

Figure 3c presents the expression patterns for mature OLs from pediatric and adult samples, sub-dividing the pediatric group into <5 and >5-year subgroups, coinciding with our functional in vitro studies. This analysis suggested an increase in anti- vs pro-apoptotic BCL-2 family gene expression pattern with age. Figure 3d presents ratios of expression of individual pro- and anti-apoptotic genes calculated from individual donors, as well as the pooled ratio of these genes. The pooled data indicates a significant increase in the anti- vs pro-apoptotic gene expression ratio in the adult compared to the overall pediatric samples. The main difference from the adult group is derived from the younger cohort.

We could not identify age and differentiation stage-related expression patterns in BCL-2 family genes whose product activity depends on alternatively spliced products. Additional data suggest that age-related differences in anti- vs pro-apoptotic BCL-2 family gene expression is also noted in IOPCs and pOLs though these did not reach significance (Supplementary Fig. 4c, d).

To address the hypothesis that the observed lack of apoptotic cell death of the adult donor cells may reflect the activation state of BH3-only molecules, we re-examined our previously described microarray of adult human OLs under LG conditions for the expression of 25 previously characterized BH3-only subfamily members. As shown in Fig. 4a, there are significant increases in the expression of BCL2L11, BNIP3, and RAD9A under LG condition for 48 h; at this time point, there was no significant change in expression of anti-apoptotic and pro-apoptotic genes (Supplementary Fig. 5) and no significant cell death (Fig. 1). These results suggest that the intrinsic apoptotic pathway was initiated by activation of some BH3-only molecules, but then inhibited by anti-apoptotic proteins.

To directly investigate the potential contribution of BCL-2 family anti-apoptotic molecules to cell survival in human adult OLs, we used ABT-737, an inhibitor of multiple BCL-2 family anti-apoptotic molecules (mainly BCL-XL, BCL-2, and BCL-W) and WEHI-539, a specific inhibitor of BCL-XL. Addition of ABT-737 to adult donor OLs significantly increased cell death in
NG compared to control conditions, as measured by reduced number of surviving cells and increased % PI+ cells (Fig. 4b, c). Cell process extension was also reduced (Supplementary Fig. 6). There was also a significant increase in % TUNEL+ cells (Fig. 4d) indicating that the adult OLs have the capacity to activate the BCL-pro-apoptotic cascade if anti-apoptotic proteins are inhibited. The relative lack of effect of WEHI-539 suggests that inhibiting BCL-XL alone is not sufficient to inhibit apoptosis.

Contribution of autophagy pathway genes to age-related OL susceptibility to metabolic injury. To determine whether differences in the relative baseline expression of autophagy genes contributed to the observed age and differentiation linked injury responses, we examined the expression of a select number of genes contributing to the autophagy response in relation to these variables. As reviewed in49,52 autophagy can be divided into four stages: initiation, nucleation, elongation and fusion. As shown in Fig. 5a, we detected a trend to decreased expression of lysosome-related genes in fetal total OL-lineage cells as compared to pediatric and adult OLs; in particular, LAMP1 and LAMP2 were significantly downregulated. Consistent age-related differences in expression of genes involved in autophagy initiation, nucleation, and elongation were not detected (Supplementary Fig. 7).
We did not detect differences in expression of autophagy genes involved in autophagy initiation in OLs under 48 h of glucose deprivation with the exception of PIK3CG that is downregulated (Fig. 5b). We did not detect a significant change in the expression levels of the elongation genes with glucose deprivation alone (Fig. 5c). Expression of genes encoding LC3 (MAP1LC3B) and p62 (SQSTM1) that were measured in the protein assays were suggestively increased (Fig. 5c). Regarding the expression of genes involved in fusion of lysosomes and autophagosomes (Fig. 5d), only VAMP8 is downregulated under low glucose. Among the genes that are involved in the lysosome formation (Fig. 5e), cathepsins C, H and O are downregulated although there is no change in cathepsins B, D, and L.

To determine whether glucose deprivation conditions at a time prior to cell death were inducing a potential protective autophagy response, we treated cultures with chloroquine, which inhibits the fusion of autophagosomes with lysosomes 64 (Fig. 6a–c). We observed that chloroquine did not increase cell death in the human OLs under optimal culture conditions (N1) but significantly increased cell death (% PI+ cells) in glucose deprivation conditions (Fig. 6a–c). Cell process extension was also reduced (Supplementary Fig. 6). To further investigate the engagement of autophagy in the response of the OLs to LG/NG conditions and the effect of chloroquine, we analyzed the protein levels of the autophagosome components LC3 and p62 by western blot. We detected an increase in the levels of these markers in these conditions when combined with chloroquine (Fig. 6d–f). This was not seen when cells were cultured in optimal conditions. These results indicate that autophagy is activated in glucose deprivation conditions. Accumulation of autophagosomes in these cells indicate an impairment in the fusion with lysosomes induced by chloroquine. These combined functional and Western blot studies support the early protective effects of the autophagy response.

**Discussion**

Our data identify BCL-2 family and autophagy pathways as contributors to age-linked responses of human OL lineage cells to metabolic injury. The viability of the cells isolated immediately from the surgical samples allowed us to perform both whole-cell scRNA seq, which includes cytoplasmic RNA in contrast to single nucleus studies, and complementary in vitro functional assays. Samples were obtained from normal appearing tissue, within the corridor required to access the pathologic site. The status of the samples was confirmed by histopathologic analysis. The metabolic insult used was designed to model focal ischemic conditions found in MS lesions and in the penumbra of focal pediatric ischemic/hemorrhagic events.

The functional in vitro injury data indicate that under the stress conditions used (combining LG/NG with reduced nutrient supplements), human fetal OL lineage cells (O4+) were highly susceptible to cell death (within 24–48 h), with the majority of cells being TUNEL+. The OLs derived from the pediatric age samples were more resistant than the fetal cells but more susceptible to injury than the adult cells. The pediatric OLs showed measurable, although limited, apoptosis. Our data that active cell death pathways are prominent in early human OPCs in response to metabolic insults are supportive of findings from rat models of hypoxic cerebral hypoxia-ischemia. The latter showed that apoptotic mechanisms were several-fold more pronounced in
immature than in juvenile and adult brains. For adult OLs, consistent with our previous report, the delayed cell death was not linked to induction of active cell death pathways.

The bioinformatics data provides insight into the molecular basis for the age-related functional injury responses that we detected. We selected representative members of the BCL-2 pathway that are well documented to be pro- or anti-apoptotic. Using the total OL population, we found that the highly injury susceptible fetal cells, containing the early OPC population, expressed the highest levels of pro-apoptotic genes. With OL differentiation, there is skewing to greater anti- vs pro-apoptotic gene expression. Our observation that pediatric donor mature OLs cells still exhibit a relative increase in the expression of pro- vs anti-apoptotic genes compared to the adult derived cells, is consistent with our observed age-related susceptibility to injury. Our in vitro studies showing that blocking anti-apoptotic genes results in significant apoptotic cell death under the LG conditions, indicate the functional relevance of the relative skewing to anti- vs pro-apoptotic gene expression in OLs. Our data suggest that anti-apoptotic genes are impeding the BH3-only family molecules, observed to be activated, from inducing the apoptosis pathway. BH3-only family members can be triggered by multiple pathologic conditions, including hypoxia.

The cell death induced by the metabolic insult used in this study is likely closely linked to energy failure. We previously documented immunocytochemically that the metabolic conditions used in the current study increased LC3 expression, an indicator of autophagy activation in adult human OLs. We now confirm by Western blotting for p62 and MAP1LC3B that autophagy is activated in these cells and demonstrate that the response is initially protective, based on the increased cell death in the presence of chloroquine. The bioinformatics data derived from immediately ex vivo cells indicate that the fetal OL lineage cells that are highly susceptible to metabolic stress, have reduced expression of the lysosome forming genes, which are an integral part of the autophagy pathway. Our observations seem compatible with those of Neumann et al. that autophagy pathway gene expression is upregulated in A2B5 antibody selected progenitor cells in aged rats; these cells overall had reduced stem cell properties.
The microarray data from the adult human OLS cultured in LG for 2 days (the time when autophagy is activated) indicate that while expression of most genes involved in encoding the autophagy pathway are unchanged, a limited number of genes were downregulated. These included PIK3CG, whose gene product inhibits autophagy initiation47, and VAMP8, which encodes a SNARE protein that is necessary for the attachment of lysosomes to autophagosomes52. Among the genes involved in lysosome formation, cathepsins C, H, and O are downregulated although there is no change in cathepsins B, D, and L. This downregulation may reduce the digestion capacity of lysosomes, although it is possible that the overall concentration of cathepsins would be sufficient. p62 and LC3 are suggestively upregulated. We did not detect a significant change in the expression levels of elongation genes, including those encoding p62 and LC3. We consider that some downregulation of genes under our LG conditions can reflect overall reduction in metabolic activity of the cells as we have previously shown using the Seahorse bioanalyzer7. Our overall results suggest that the observed autophagy activation most reflects post-translational changes.

Overall, our study provides molecular and functional data to document the susceptibility of human OL lineage cells to metabolic injury and elucidates the role of age and OL lineage cell maturity level in this process. Defining the mechanism of cell death can direct therapeutics aimed at protecting cells that may initially survive acute or chronic insults across the age spectrum, enhancing the possibility for their participation in subsequent myelin repair9,10.

Methods

Human cell samples. Brain tissue samples were obtained from surgical procedures. Anonymized adult samples were obtained via the Department of Neurology at the Montreal Neurological Institute and Hospital (MNI) and pediatric samples from the Montreal Children’s Hospital with written consent from families. 2nd trimester (14–17 weeks) fetal samples were obtained from the University of Washington Birth Defects Research Laboratory (MP-37-2014-540; 13-244-PED; eReviews_3345). Demographics of the pediatric patients are given in Supplementary Table 1. Adult donors ranged in age from 30–75 years; all had non-tumor related focal epilepsy. Use of pediatric and adult tissues where approved by the MNI Neurosciences Research Ethics Board (Protocol ANTJ 1988/3) and the use of pediatric tissues approved by the Montreal Children’s Hospital Research Ethics Board.

Cell isolation. Tissues from the surgical corridor from the adult and pediatric samples were collected into CUSA bags. Tissue derived from the CUSA bags was subjected to trypsin digestion followed by Percoll gradient centrifugation in order to obtain a myelin-depleted whole-cell fraction comprised mainly of OLS and microglia with few if any astrocytes or neurons. The scRNA seq data from the adult and pediatric surgical samples were derived from sequencing this total cell population overnight to remove adherent microglia. Fetal cell isolation does not require a Percoll gradient step but in order to enrich for OL cells for our functional assays, we used immune-magnetic beads coated with O4 antibody (IgM38 to collect rare (1–5%) O4+ cells.

Cell culture. After selection, cells were plated in 96-wells or 24-wells plates coated with poly-lysine and extra-cellular matrix at a density of 3 × 104 cells (96-wells plate) or 1 × 105 cells (24-wells plate) per well. Cells were cultured in DMEM-F12 media supplemented with N1 (Sigma, Oakville, ON, Canada). For metabolic deprivation experiments, cells were cultured in DMEM containing 0.25 g/l of glucose (LG) or with no glucose added (NG).

Immunocytochemistry. Cells were live stained with propidium iodide (PI; Invitrogen) (1:200) for cell viability measurement and with O4 monoclonal antibody (R&D Systems, Minneapolis, MN) (1:200) for 15 min at 37°C and then fixed with 4% paraformaldehyde for 10 min in room temperature. Goat anti-mouse IgM Cy3 (1:500) was used as secondary antibody to O4, 30 min at room temperature. Cells were stained with a commercial TUNEL kit (Promega, Madison, WI). Cell nuclei were stained with Hoechst 33258 (1:1000). Inhibitors used in these experiments were: Chloroquine (10 µM; Sigma, Oakville, ON, Canada), WEHI-539 (10 µM; Selleckchem, Houston, TX) and ABT-737 (10 µM; Selleckchem, Houston, TX).

Western blot. SDS-PAGE was run with 5–10 µg of protein in each sample in 15% acrylamide gels. Proteins were transferred to a PVDF membrane. The membranes were blocked with 5% milk and probed with the primary antibodies overnight at 4°C.

Fig. 6 Contribution of the autophagy pathway to protecting OLS from metabolic injury. a–c Protective effects of autophagy in human adult OLS. Cell death measured by % PI+ cells of human adult OLS cultured in optimal culture media (N1), in low glucose media (LG) and in combined treatment with chloroquine (N1 + CQ; LG + CQ) after two (a), four (b) and six days (c). Addition of CQ results in increase % PI+ cells at day 4 and 6. N = 5 independent biological samples. d–f Representative western blot for the combined treatment of N1, LG, and NG with and without chloroquine after two days (N = 3 independent biological samples) (d) and quantification of the relative expression compared to actin of LC3 II (e) and p62 (f). Mean ± SEM for each condition in the figure. Statistical significance was verified by ANOVA/Tukey test *(<0.05), **(<0.01), ***(<0.001).
**Data availability**

Source data for figures are provided at Supplementary Data 1. Uncropped scans of western blot are shown in Supplementary Figs. 8–10. Microarray and RNA-seq data were deposited at GEO under accession number GSE160813. Immunocytochemistry images will be provided upon request.

Received: 1 July 2020; Accepted: 1 December 2020; Published online: 04 January 2021

**References**

1. Kuhlmann, T. et al. An updated histological classification system for multiple sclerosis lesions. *Acta Neuropathol.* 133, 13–24 (2017).

2. Lucchinetti, C. F., Bruck, W. & Lassmann, H. Evidence for pathogenic heterogeneity in multiple sclerosis. *Ann. Neurol.* 56, 308 (2004).

3. Prineas, J. W. & Parratt, J. D. Oligodendrocytes and the early multiple sclerosis lesion. *Ann. Neurol.* 72, 18–31 (2012).

4. Barnett, M. H. & Prineas, J. W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. *Ann. Neurol.* 55, 458–468 (2004).

5. Ludwin, S. K. & Johnson, E. S. Evidence for a “dying-back” gliaopathy in demyelinating disease. *Ann. Neurol.* 9, 301–305 (1981).

6. Rodriguez, M., Scheithauer, B. W., Forbes, G. & Kelly, P. J. Oligodendrocyte injury is an early event in lesions of multiple sclerosis. *Mayo Clin. Proc.* 68, 627–636 (1993).

7. Cui, Q. L. et al. Sublethal oligodendrocyte injury: A reversible condition in multiple sclerosis? *Ann. Neurol.* 81, 811–824 (2017).

8. Rone, M. B. et al. Oligodendrogliaopathy in multiple sclerosis: low glycolytic metabolic rate promotes oligodendrocyte survival. *J. Neurosci.* 36, 4694–4707 (2016).

9. Yeung, M. S. Y. et al. Dynamics of oligodendrocyte generation in multiple sclerosis. *Nature* 566, 538–542 (2019).

10. Duncan, I. D. et al. The adult oligodendrocyte can participate in remyelination. *Proc. Natl Acad. Sci. USA* 115, E11807–E11816 (2018).

11. Lassmann, H. & van Horsen, J. Oxidative stress and its impact on neurons and glia in multiple sclerosis lesions. *Biochim. Biophys. Acta* 1862, 506–510 (2016).

12. Mahad, D. H., Trapp, B. D. & Lassmann, H. Pathological mechanisms in progressive multiple sclerosis. *Lancet Neurol.* 14, 183–193 (2015).

13. Aboul-Enein, F. et al. Preferential loss of myelin-associated glycoprotein reflects hyponxia-like white matter damage in stroke and inflammatory brain diseases. *J. Neuropathol. Exp. Neurol.* 62, 25–33 (2003).

14. Stadelmann, C. et al. Tissue preconditioning may explain eccentric lesions in Baló’s type of multiple sclerosis. *Brain* 128, 979–987 (2005).

15. Trapp, B. D. & Stys, P. K. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. *Lancet Neurol.* 8, 280–291 (2009).

16. D’Haeseleer, M. et al. Cerebral hypoperfusion: a new pathophysiological concept in multiple sclerosis? *J. Cereb. Blood Flow Metab.* 35, 1406–1410 (2015).

17. Dutta, R. & Trapp, B. D. Gene expression profiling in multiple sclerosis brain. *Neurobiol. Dis.* 45, 108–114 (2012).

18. Franklin, R. J. M., Ffrench-Constant, C. & Regenerating, C. N. myelin – from mechanisms to experimental medicines. *Nat. Rev. Neurosci.* 18, 753–769 (2017).

19. Cui, Q. L. et al. Oligodendrocyte progenitor cell susceptibility to injury in multiple sclerosis. *Am. J. Pathol.* 183, 516–523 (2015).

20. Schneider, J. & Miller, S. P. Preterm brain injury: White matter injury. *Handb. Clin. Neurol.* 162, 155–172 (2019).

21. Volpe, J. J. Neonatal encephalopathy: an inadequate term for hypoxic-ischemic encephalopathy. *Ann. Neurol.* 72, 156–166 (2012).

22. Gunn, A. J. & Thoresen, M. Neonatal encephalopathy and hypoxic-ischemic encephalopathy. *Handb. Clin. Neurol.* 162, 217–237 (2019).

23. Glass, H. C. Hypoxic-ischemic encephalopathy and other neonatal encephalopathies. *Continuum (Minn.)* 24, 57–71 (2018).

24. Plouin, P. & Kaminska, A. Neonatal seizures. *Handb. Clin. Neurol.* 111, 467–476 (2013).

25. Back, S. A. White matter injury in the preterm infant: pathology and mechanisms. *Acta Neuropathol.** Acta Neuruphysiol.* 134, 331–349 (2017).

26. Back, S. A. et al. Late oligodendrocyte progenitors coincide with the developmental window of vulnerability for human perinatal white matter injury. *J. Neurosci.* 21, 1302–1312 (2001).

27. Chang, A., Nishiyama, A., Peterson, J., Prineas, J. & Trapp, B. D. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. *J. Neurosci.* 20, 6404–6412 (2000).

28. Leong, S. Y. et al. Heterogeneity of oligodendrocyte progenitor cells in adult human brain. *Ann. Clin. Transl. Neurol.* 1, 272–283 (2014).

29. Back, S. A. et al. Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. *J. Neurosci.* 22, 455–463 (2002).
62. Kline, M. P. et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent

30. Giacci, M. K. et al. Oligodendroglia are particularly vulnerable to oxidative

ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-01557-1

31. Marin, M. A. & Carmichael, S. T. Mechanisms of demyelination and

35. Rao, V. T. S. et al. Distinct age and differentiation-state dependent metabolic

48. Galluzzi, L., Bravo-San Pedro, J. M., Blomgren, K. & Kroemer, G. Autophagy

47. Galluzzi, L. et al. Molecular de

51. Munson, M. J. & Ganley, I. G. MTOR, PIK3C3, and autophagy: signaling the

37. Kale, J., Osterlund, E. J. & Andrews, D. W. BCL-2 family proteins: changing

53. Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of

40. Itoh, T., Itoh, A. & Pleasure, D. Bcl-2-related protein family gene expression

55. Neumann, B. et al. Metformin restores CNS remyelination capacity by

57. Esmonde-White, C. et al. Distinct function-related molecular pro

39. Guo, K. et al. Hypoxia induces the expression of the pro-apoptotic gene

541 (2018).

58. Jäkel, S. et al. Altered human oligodendrocyte heterogeneity in multiple

486

mechanisms.

Autophagy

J. Cell Sci.

fusion.

Cell Death Differ.

485.e478 (2019).

460 (2009).

71. Zhang, F., Wu, Y. & Tian, W. A novel approach to remove the batch effect of

69. Stuart, T. et al. Comprehensive integration of single-cell data. Nature

403, 1549

118, 549

115, 547 (2019).

17, 356 (2014).

753 (2008).

744 (1996).

150, 1400–1412 (2010).

1081–1087 (2012).

© The Author(s) 2021

Appendix

The authors declare no competing interests.

Author contributions

Milton Guilherme Forestieri Fernandes designed and performed the studies related to BCL-2 and autophagy regulation of cell injury. Julia Luo designed and analyzed the single cell sequencing studies. Qiao-Ling Cui contributed to design and performance of in vitro functional studies; responsible for cell isolation and culture. Kelly Perlman participated in design and analysis of the single cell sequencing studies. Floran Permin contributed to design and performance of in vitro functional studies. Moein Yaqubi participated in design and analysis of the single cell sequencing studies. Jeff Hall designed protocol to provide adult surgical specimens. Roy Dudley designed protocol to provide pediatric surgical specimens. Myrram Sour participated in design of pediatric surgical studies and writing of manuscript. Charles Couturier participated in design and analysis of the single cell sequencing studies. Kevin Petrecca designed protocol to provide adult surgical specimens; participated in design and analysis of the single cell sequencing studies. Catherine Larochelle participated in characterization of oligodendrocyte populations. Luke Healy participated in design and analysis of the single cell sequencing studies and preparation of the manuscript. Jo Anne Stratton participated in design and analysis of the single cell sequencing studies and preparation of the manuscript. Timothy E. Kennedy contributed to design of overall study and preparation of the manuscript. Jack P. Antel coordinated the design of the study and preparation of the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s42003-020-01557-1.

Correspondence and requests for materials should be addressed to J.P.A.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless noted otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021